Ocular Therapeutix, Inc.OCULNASDAQ
LOADING
|||
OCUL Revenue Growth (YoY Quarterly)•-5.71%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +2.28% | +15.41% | -27.59% | -18.14% | -5.71% |
| Gross Profit Growth | +1.17% | +18.17% | -29.83% | -22.88% | -7.89% |
| EBITDA Growth | -950.26% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +110.39% | +58.62% | +28.31% | +4.08% | +10.14% |
| Weighted Average Shares Diluted Growth | +96.13% | +54.42% | +28.31% | +4.08% | +10.14% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +28.17% | +23.72% | -4.99% | +0.60% | +1.76% |
| Inventory Growth | +6.56% | +31.89% | +27.00% | +19.32% | +45.03% |
| Asset Growth | +201.98% | +81.68% | -24.68% | -12.72% | -16.21% |
| Book Value per Share Growth | +2030.63% | +118.15% | -49.20% | -22.18% | -33.40% |
| Debt Growth | -9.51% | -9.12% | +2.44% | +2.74% | +2.51% |
| R&D Expense Growth | +146.71% | +153.10% | +106.69% | +77.01% | +41.30% |
| SG&A Expenses Growth | +27.43% | +47.30% | +25.34% | -5.36% | +27.63% |
1 / 4